Skip to main content
. Author manuscript; available in PMC: 2014 Sep 9.
Published in final edited form as: Cochrane Database Syst Rev. 2011 Dec 7;(12):CD006528. doi: 10.1002/14651858.CD006528.pub2

Comparison 6. Funnel plot analysis: primary outcome (response) at end of the acute-phase treatment.

Outcome or subgroup title No. of studies No. of participants Statistical method Effect size
1 vs all compounds 26 4882 Risk Ratio (M-H, Fixed, 99% CI) 1.05 [0.99, 1.12]
 1.1 vs Amitriptyline 6 929 Risk Ratio (M-H, Fixed, 99% CI) 0.95 [0.82, 1.11]
 1.2 vs Clomipramine 1 174 Risk Ratio (M-H, Fixed, 99% CI) 0.97 [0.74, 1.26]
 1.3 vs Doxepin 1 163 Risk Ratio (M-H, Fixed, 99% CI) 0.95 [0.71, 1.26]
 1.4 vs Nortriptyline 1 235 Risk Ratio (M-H, Fixed, 99% CI) 0.94 [0.59, 1.49]
 1.5 vs Citalolpram 1 270 Risk Ratio (M-H, Fixed, 99% CI) 0.96 [0.85, 1.09]
 1.6 vs Fluoxetine 5 622 Risk Ratio (M-H, Fixed, 99% CI) 1.18 [1.00, 1.39]
 1.7 vs Paroxetine 3 726 Risk Ratio (M-H, Fixed, 99% CI) 1.13 [0.93, 1.38]
 1.8 vs Sertraline 2 596 Risk Ratio (M-H, Fixed, 99% CI) 0.99 [0.83, 1.17]
 1.9 vs Fluvoxamine 1 412 Risk Ratio (M-H, Fixed, 99% CI) 1.05 [0.86, 1.28]
 1.10 vs Venlafaxine 2 415 Risk Ratio (M-H, Fixed, 99% CI) 1.24 [0.96, 1.60]
 1.11 vs Trazodone 2 300 Risk Ratio (M-H, Fixed, 99% CI) 1.21 [0.91, 1.61]
 1.12 vs Reboxetine 1 40 Risk Ratio (M-H, Fixed, 99% CI) 1.0 [0.55, 1.82]